Novartis

Dae Wook Lee

Bio: Dr. Dae Wook Lee is a Medical Director of Novartis Korea in Cardiology, Renal, Metabolism, Neuroscience, and Gene Therapy. He was Head of Medical Portfolio Management in Rare Disease, Gastroenterology, PDT, Neuroscience, and New Molecular entities from the Asia-Pacific Region of Takeda Pharmaceutical Ltd Pte. He obtained his Medical Degree from the University of Warwick, U.K., awarded MbChB Medicine & Surgery, and completed MSC Genetic Epidemiology at the Medical Research Unit in the University of Sheffield, U.K., with an additional BSc Biomedical Science degree. He also holds an Executive MBA from Harris College of Business, Faulkner University in North Alabama. Dr. Lee received the Best Research Award in the International Research Awards of Cardiology and Cardiovascular Medicine in 2022. His main clinical research interests lie in genetics and novel medical statistical analysis of Rare Diseases, including Cardiology, Rare Hematology, Rare Metabolic Diseases including Fabry & Gaucher’s Disease, Rare Immunology including Hereditary AngioEdema (HAE), etiology and pathophysiology of inflammatory bowel disease (IBD), and Rare Neuroscience disease including Paediatric Epilepsy and Narcolepsy Type 1. One of his recent publications includes Network Meta-analysis of Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients and Retrospective Analysis of Ulcerative Colitis Real-world Evidence Implementing Exploratory Propensity Score Matching (PSM) analysis. Dr. Lee is also a member of the Korean Society of Pharmaceutical Medicine (KSPM).

The rapid progress in generative AI has unlocked unprecedented opportunities for innovation and discovery across various domains, and the biotechnology industry is poised to reap the countless benefits of this transformative technology.

Advancement of Generative AI

Generative AI, a groundbreaking branch of artificial intelligence, has demonstrated remarkable capabilities in producing novel and diverse data samples, from molecular structures to biological images. This technology has found its way into the heart of biotechnology, revolutionizing how researchers approach challenges such as drug discovery, protein engineering, and personalized medicine.

Implication of Generative AI in Drug Discovery

In the drug discovery field, generative AI models like Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs) have shown immense potential. These models can generate novel molecular structures with desired properties, significantly accelerating the identification of potential drug candidates and streamlining the drug development process. For instance, researchers have leveraged generative AI to design and optimize enzyme catalysts, antibodies, and other therapeutic agents with enhanced functionalities. Such advancements can revolutionize the pharmaceutical industry, propelling the development of more targeted and effective treatments for a wide range of medical conditions.

Biological Image Synthesis with AI

Beyond drug discovery, generative AI has also made remarkable strides within the biological image synthesis realm. By generating realistic and diverse synthetic images of cells, tissues, and organisms, this technology has enabled researchers to augment training datasets, improve the performance of machine learning models, and conduct in silico testing of novel algorithms. Such advancements boost solutions like virtual screening, disease diagnosis, and therapeutic monitoring, ultimately leading to more accurate and personalized healthcare solutions.

Analysis of Omics and Genomics Data

Furthermore, generative AI has found its way into the omics data analysis and generation, including genomics, transcriptomics, proteomics, and metabolomics. Synthetic omics data generated by these models can supplement experimental data, simulate biological processes, and validate computational models for accelerating the discovery of biomarkers and therapeutic targets. This synergy between generative AI and biotechnology holds immense promise in advancing our understanding of complex biological systems and paving the way for more personalized and targeted therapies.

“As the field continues to evolve, the collaboration between generative AI and biotechnology will undoubtedly pave the way for a future where scientific breakthroughs and medical advancements are more accessible and impactful than ever before.”

R&D Footprint with Forward-looking AI Implication

While challenges such as data quality, interpretability, and data mapping still need to be addressed, integrating generative AI into biotechnology research and development has already demonstrated its transformative potential. From streamlining literature-based research to automating the generation of scientific content, it is becoming an indispensable tool in the everyday operations of biotechnology laboratories. As we look to the future, the continued advancements in generative AI are poised to play a pivotal role in solving the core challenges of the biotechnology industry, from personalized medicine to targeted drug therapies. The synergy between these groundbreaking technologies holds the key to unlocking new frontiers in the pursuit of scientific discoveries that can profoundly impact human health and well-being.

In conclusion, the integration of generative AI into the biotechnology landscape is not just a promising trend but a transformative force that is reshaping the way we approach and address some of the most pressing healthcare challenges of our time. By harnessing the innovative potential of this technology, the industry makes significant strides in improving patient outcomes, accelerating drug discovery and development, and advancing personalized medicine. As the field continues to evolve, the collaboration between generative AI and biotechnology will undoubtedly pave the way for a future where scientific breakthroughs and medical advancements are more accessible and impactful than ever before.